Phase 2 Asthma Trial, Recruiting NCT05028153 Sponsor: Copenhagen Studies on Asthma in Childhood Condition: Asthma
Back to Asthma

Phase 2 Asthma Trial, Recruiting

NCT05028153
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children who have had one or more episodes of asthma-like symptoms, or who have been treated with certain asthma-related medications (a fast-acting reliever inhaler alone, or combined with a preventer inhaler, and possibly an additional medication called a leukotriene receptor antagonist)
  • Children who are between 12 and 71 months old (approximately 1 to 6 years of age)
  • Families where the parent or guardian agrees to enrol the child and is willing to follow the trial procedures
  • Families where the parent or guardian speaks fluent Danish

Who may not be able to join:

  • Children with a known allergy to a group of antibiotics called macrolides
  • Children with a known liver problem
  • Children with a known kidney problem
  • Children known to have a neurological or psychiatric condition
  • Children with a known heart electrical condition called a prolonged QT interval (whether present from birth or developed later)
  • Children known to have a significantly slow heart rate, an irregular heartbeat, or severe heart failure
  • Children showing signs of pneumonia at the time of enrolment, including a very fast breathing rate (over 50 breaths per minute), a high fever (over 39°C), or a raised level of a blood marker called C-reactive protein (over 50)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jakob Stokholm, MD, PhD, University Hospital of Copenhagen, DK-2820 Gentofte, Denmark

Phone: +4538677360

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Copenhagen Studies on Asthma in Childhood
Registry
ClinicalTrials.gov
Start date
14 November 2022
Est. completion
13 November 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Duration in days of the asthma-like episode from the start of randomization.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov